Victoria Smith

Company: Amphivena

Job title: CSO

Bio:

Victoria Smith PhD has over 23 years of experience in biologics drug discovery and development. She began her career in Biotechnology at Genentech Inc, where she applied her research background in genomics to both target discovery and for the characterization and development of antibody drug conjugates for solid tumors. Dr Smith then joined Arresto Biosciences at its inception, taking on roles of increasing responsibility with the growth of the company, to become Vice President of Research and Preclinical Development. At Arresto, Dr Smith led the translation of novel mechanisms for targeting the tumor microenvironment, fibrosis and inflammatory disease to clinical development candidates. Upon the acquisition of Arresto by Gilead Sciences in 2011, Dr Smith led biologics research and translational studies as the Senior Director of Biologics and Target Biology. In the course of her role at Gilead, Dr Smith built an antibody engineering group, initiated new research projects, provided cross functional Research project support and oversight, supported clinical development for biologics projects from phases 1-3, and continued to deepen her expertise in oncology and immune oncology while also expanding her knowledge in new areas such as virology. Dr Smith has a B.S. from the University of Western Australia and a Ph.D. from Cambridge University, UK, and she was a Research and Post-Doctoral Fellow at Stanford University in the Departments of Biochemistry and Genetics. She is an author on numerous peer reviewed scientific publications and patents.

Seminars:

AMV564 Relieves Immune Suppression Through Selective Targeting of CD33 4:35 pm

AMV564 selectively depletes leukemic blasts in AML In addition, AMV564 targets myeloid derived suppressor cells T cell activation is apparent with continuous intravenous infusion (AML) or subcutaneous administration (solid tumors)Read more

day: Day One